Literature DB >> 1689955

Maternal serum alpha-fetoprotein (MSAFP) patient-specific risk reporting: its use and misuse.

J N Macri1, R V Kasturi, D A Krantz, E J Cook, J W Larsen.   

Abstract

Fundamental to maternal serum alpha-fetoprotein screening is the clinical utility of the laboratory report. It follows that the scientific form of expression in that report is vital. Professional societies concur that patient-specific risk reporting is the preferred form. However, some intermediate steps being taken to calculate patient-specific risks are invalid because of the erroneous assumption that multiples of the median (MoMs) represent an interlaboratory common currency. The numerous methods by which MoMs may be calculated belie the foregoing assumption.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689955      PMCID: PMC1683609     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  16 in total

1.  Maternal serum alpha-fetoprotein screening. II. Pitfalls in low-volume decentralized laboratory performance.

Authors:  J N Macri; R V Kasturi; D A Krantz; M G Hu
Journal:  Am J Obstet Gynecol       Date:  1987-03       Impact factor: 8.661

2.  Maternal serum alpha-fetoprotein screening, maternal weight, and detection efficiency.

Authors:  J N Macri; R V Kasturi; D A Krantz; K E Koch
Journal:  Am J Obstet Gynecol       Date:  1986-10       Impact factor: 8.661

3.  Maternal weight adjustment and low serum alpha-fetoprotein values.

Authors:  G E Palomaki; G J Knight; E M Kloza; J E Haddow
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

4.  Implementation of a screening program for diagnosing open neural tube defects: selection, evaluation, and utilization of alpha-fetoprotein methodology.

Authors:  R L Christensen; M R Rea; G Kessler; J P Crane; R Valdes
Journal:  Clin Chem       Date:  1986-10       Impact factor: 8.327

5.  Critical issues in prenatal maternal serum alpha-fetoprotein screening for genetic anomalies.

Authors:  J N Macri
Journal:  Am J Obstet Gynecol       Date:  1986-08       Impact factor: 8.661

6.  Maternal serum alpha-fetoprotein screening: effects of weight adjustment.

Authors:  L C Kazazian; J R Niebyl; J M Joseph
Journal:  Am J Obstet Gynecol       Date:  1987-09       Impact factor: 8.661

Review 7.  Decision analysis.

Authors:  S G Pauker; J P Kassirer
Journal:  N Engl J Med       Date:  1987-01-29       Impact factor: 91.245

8.  Clinical interpretation of maternal serum alpha-fetoprotein concentrations.

Authors:  M J Adams; G C Windham; L M James; F Greenberg; J A Clayton-Hopkins; C B Reimer; G P Oakley
Journal:  Am J Obstet Gynecol       Date:  1984-02-01       Impact factor: 8.661

9.  Variability in predicted rates of Down syndrome associated with elevated maternal serum alpha-fetoprotein levels in older women.

Authors:  E B Hook
Journal:  Am J Hum Genet       Date:  1988-08       Impact factor: 11.025

10.  Maternal serum alpha-fetoprotein, age, and Down syndrome risk.

Authors:  G E Palomaki; J E Haddow
Journal:  Am J Obstet Gynecol       Date:  1987-02       Impact factor: 8.661

View more
  1 in total

1.  All MoMs are not equal: some statistical properties associated with reporting results in the form of multiples of the median.

Authors:  J C Bishop; F D Dunstan; B J Nix; T M Reynolds; A Swift
Journal:  Am J Hum Genet       Date:  1993-02       Impact factor: 11.025

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.